Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer
Status:
Completed
Trial end date:
2000-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy
using raloxifene may fight endometrial cancer by reducing the production of estrogen.
PURPOSE: Phase II trial to study the effectiveness of raloxifene in treating patients who
have persistent or recurrent endometrial cancer.